Journal of Bone and Soft Tissue Tumors (JBST) License
Journal of Bone and Soft Tissue Tumors (JBST) by http://jbstjournal.com/ is licensed under https://creativecommons.org/licenses/by-nc-sa/4.0/
Based on a work at http://jbstjournal.com/.
Permissions beyond the scope of this license may be available at editor.jbst@gmail.com
Journal of Bone and Soft Tissue Tumors (JBST) is the official Journal of The Indian Musculo Skeletal Oncology Society
Journal of Bone and Soft Tissue Tumors – Unique Status
Vol 2 | Issue 2 | May – Apr 2016 | page:1-2 | Dr Yogesh Panchwagh & Dr Ashok Shyam.
Author: Dr Yogesh Panchwagh [1] & Dr Ashok Shyam [1,2].
[1]Orthopaedic Oncology Clinic, Pune, India.
[2] Indian Orthopaedic Research Group, Thane, India
[3] Sancheti Institute for Orthopaedics &Rehabilitation, Pune, India.
Address of Correspondence
Dr. Yogesh Panchwagh.
Orthopaedic Oncology Clinic, 101, Vasant plot 29, Bharat Kunj Society -2, Erandwana, Pune – 38, India.
Email: drpanchwagh@gmail.com
Journal of Bone and Soft Tissue Tumor (JBJST) enjoys a special status in being one of the unique journals exclusively dedicated to bone and soft tissue tumors. The clinical expertise and technological development has been very rapid in this field and JBST already had a demand among the clinicians involved in taking care of musculoskeletal Oncology. JBST has successfully filled this vacuum that existed and has received great support from musculoskeletal tumor surgeons and clinicians. The platform provided by JBST has been used worldwide to access articles and also to submit original research. There are other factors that further add to its uniqueness. One of the most unique point is that this is a journal that is initiated by clinicians. JBST was conceived and initiated by people who were directly involved in care of musculoskeletal tumor patients. They perceived the need of such a journal and were instrumental in moulding it in its current shape. Another unique point of JBST is that it is not a pure research journal but also a tool to educate the young trainees and practitioners. JBST has a dedicated symposium in each issue which provides a comprehensive overview of the subject along with recent updates. This is very helpful for students, trainees and practitioners of the subject. These symposium articles are written by carefully solicited authors that have years of practical experience which add to the flavour of the article. The authors are requested to add the practical tips and cases to these symposium reviews to make it much more clinically relevant rather than simply publish a theoretical review of literature. Special attention is given to students in JBST and a students corner is published in every issue which is a brief overview article on a single bone tumor. This is specially created with keeping students in mind and is co-created with help of a trainee or a student. This has received excellent response as far as student readership is concerned and we thank Dr Ashish Gulia for initiating and supporting this initiative. Oncomedia is another unique part of JBST where recent conferences, upcoming conferences and new updates regarding bone and soft tissue tumors are listed. Videos and other academic materials are also included in this section. It’s a very unique source of information to our readers and is presented in a very reader friendly manner.This particular issue is also unique as it features and is dedicated to one of the most prestigious orthopaedic oncology unit in India from Tata Memorial Hospital (TMH) in Mumbai. The guest editorial is been contributed by the TMH team and it traces the journey of the hospital from its inception till today. JBST plans to continue this feature where such units, who have contributed significantly to growth of musculoskeletal oncology will be featured. We intend to include this a regular feature in JBST. Another feature that we really wish to include is academic interview, featuring individual personalities in the field of musculoskeletal oncology. Other journals from orthopaedic research group like trauma international and International Journal of Paediatric Orthopaedics have been regularly publishing such academic interviews. Hopefully JBJST will start this feature by next year. The JBST team is always looking for making the journal better with the aim to provide the best content to its reader which is presented in the most accessible and easy format. Being focussed on the subject of bone and soft tissue tumours and created and run by focussed and expert team has helped the journal achieve a unique status already and with help of the entire fraternity it is sure to grow further. If you have any suggestions for the editorial team, please feel free to write to us.
Dr Yogesh PachwaghDr Ashok Shyam
(Abstract Full Text HTML) (Download PDF)
Like this:
PVNS talus in a patient treated for chondral lesion in ipsilateral calcaneum: A case report and review of literature
Vol 3 | Issue 2 | Sep-Dec 2017 | Page 10-13 | Apurv Gabrani, Hitesh Dawar, Deepak Raina, Surbhit Rastogi
Authors: Apurv Gabrani [1], Hitesh Dawar [1], Deepak Raina [1], Surbhit Rastogi [1].
[1] Indian Spinal Injuries Centre, New Delhi.
Address of Correspondence
Dr . Apurv Gabrani
Ah-22, Shalimar Bagh, New Delhi-110088
Email: apurvgabrani@gmail.com
Abstract
Introduction: PVNS is a locally aggressive synovial proliferative disorder of unknown etiology and has been described in the foot and ankle in previous literature. A case of PVNS in the talus has been described in a patient treated for ipsilateral calcaneal chondral lesion.
Case Report: A 56 year old male presented with pain in his left ankle of 4 months duration. On investigation, he was found to have a well defined lytic lesion in the left calcaneum on x-ray. MRI showed a hyper intense lesion on T2WI. A needle biopsy revealed chondrogenic tumor which was managed by extended curettage. At 12 months follow up, patient presented with recent onset pain over the anterior aspect of left ankle which showed hypo density over the supero-anterior aspect of the talus and MRI showed ill defined hypo intense lesion on T2WI and hyper intense lesion on T1WI. The lesion increased in size on repeat MRI 6 weeks later. He was managed with synovectomy and debridement with core needle biopsy of talus. Histopathological examination revealed features consistent with PVNS. Patient remains asymptomatic at 1 year follow up after surgery.
Conclusion: A double primary lesion although rare, does exist and any recurrence should be viewed at with equal degree of suspicion as the primary lesion.
Keywords: Pigmented villonodular synovitis (PVNS), Talus, Calcaneum, Double Primary lesion, Chondral lesion.
References
1. Granowitz S.P., D’Antonio, j., and Mankin, H.L. The pathogenesis and long term results of PVNS. Clin Orthop 1976 ;114:335-351
2. Bakotic BW, Borkowski P. Primary soft tissue neoplasms of the foot: the clinicopathological features of 401 cases. J Foot Ankle Surg 2001; 40:29-36
3. T. Okoro, S. Isaac, R.U. Ashford, C.J. Kershaw. Pigmented villonodular synovitis of the talonavicular joint: A case report and review of the literature. The Foot 19(2009) 186-188
4. Jaffe HL, Litchtenstein L, Sutro C. Pigmented Villonodular Synovitis: bursitis and tenosynovitis. Arch Pathol 1941;31:731-65
5. Llauger J, Palmer J, Roson N. Pigmented villonodular synovitis and giant cell tumors of the tendon sheath: radiologic and pathologic features. Am J Roentgenol 1999; 172(4): 1087-91
6. Dorwart R.H., Genant H.K., Johnston W.H., and Morris J.M. PVNS of synovial joints: clinical, pathological, and radiologic features. Am J Roentgenol 1984;143:877-885
7. Sharma H, Jane MJ, Reid R. Pigmented villonodular synovitis of the foot and ankle: forty years of experience from the Scottish Bone Tumor Registry. J Foot Ankle Surg 2006;45(5): 329-36
8. Carmon W.A. Pigmented villonodular synovitis. Med Clin North Am 1947; 49:26-38
9. Young JM, Hudacek AG. Experimental production of pigmented villonodular synovitis in dogs. Am J pathol 1954;30:799
10. DeBruin J.A and Rockwood C.A. PVNS: Invasion of bone involving the knee joint. South Med J 1956; 59:466-468
11. McMaster P.E. PVNS with invasion of bone. J Bone Joint Surg 1960; 42A:1170-1183
12. Rothstein A.S. Localized PVNS of the ankle. J Am Podiatr Med Assoc1981; 71:607-610
13. Chung S.M.D., Janes J.M. Diffuse PVNS of the hip joint. J Bone Joint Surg1965; 47A:293-303
14. Bravo S.M., Winalski C.S., Weissman B.N. Pigmented villonodular synovitis. Radiol Clin North Am 1996; 34:311-26
15. Lin J, Jacobson JA, Jamadar DA, Ellis JH. Pigmented villonodular synovitis and related lesions: the spectrum of imaging findings. Am J Roentgenol 1999;172:191-7
16. Berger. I, Ehemann. V, Helmchen. B, Penzel. R, Weckauf. H. Comparative analysis of cell populations involved in the proliferative and inflammatory process in localized and diffuse pigmented villonodular synovitis: Histopathol 2004 Jul;19-3:687-92
17. Lewis R.W. Roentgen diagnosis of PVNS and synovial SA of the knee joint. Radiology1947; 49:26-38
18. Ho C.F. Chiou H.J., Chou Y.H. Peritendinous lesions. The role of high resolution ultrasonography. J. Clin. Imaging 2003;27:239-250
19. Ugai K., Morimoto K. Magnetic resonance imaging of pigmented villonodular synovitis in subtalar joint. Report of a case: Clin Orthop 1992;283:281-4
20. Myers B.W, Masi A.T. Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiological study of 166 cases and literature review. Medicine(Baltimore)1980;59(3):223-38
21. Al-Nakshabandi N.A., Ryan A.G., Choudur H.: Pigmented villonodular synovitis. Clin Radiol 2004;59:414-20
22. Babinas I., De silva U., Grimer R.J. Pigmented villonodular synovitis of the foot and ankle: a 12 year experience from a tertiary orthopedic oncology unit. J Foot Ankle Surg. 2004;43(6):407-11
23. Segler C.P. Irradiation as an adjunctive treatment of diffuse pigmented villonodular synovitis of the foot and ankle prior to tumor surgical excision. Med Hypothesis 2003;61:229-230
24. Byers P.D., Cotton R.E., Deacon O.W., Lowy M., Newmau P.H., Sissons H.A., Thomson A.D.: The diagnosis and treatment of pigmented villonodular synovitis. J Bone Joint Surg1968; 50:290.
(Abstract Full Text HTML) (Download PDF)
Like this:
Primary Intraosseous Schwannoma
Vol 3 | Issue 2 | Sep-Dec 2017 | Page 14-15| Asawari Ambekar, Chitralekha Soman.
Authors: Asawari Ambekar [1], Chitralekha Soman [1].
[1] Department of Histopathology, Mumbai Reference Laboratory, SRL Limited, Mumbai, Maharashtra, India
Address of Correspondence
Dr. Asawari Ambekar,
Reserve Bank of India Soc number 2 B 5 Gavand Path Thane West 400602
E-mail: asawariaa61@gmail.com
Abstract
Schwannomas are benign tumors arising from the peripheral nerve sheath. Neurogenic tumors of bone are extremely uncommon and they compose less than 1% of all benign tumors [1]. We present a case of intraosseous schwannoma in a 15 year old girl who presented with pain and pathological fracture of tibia. The radiology revealed an expansile and lytic lesion in the diaphysis. Histopathology confirmed the diagnosis of intraosseous schwannoma. The tumor cells were immunoreactive for S100protein. We present this case as tibial schwannoma is extremely rare and its diaphyseal location in the bone is virtually unknown.
Keywords: Schwannoma, tibia, diaphysis
References
1. Mark JM, Natalie C., Donald K.Schwannoma: A case report.The Foot and Ankle Online Journal 2009
2. Rosai, J., Ackerman, L. V. 1. &Rosai, J. (2004). Rosai and Ackerman’s surgical pathology (9th ed.). St. Louis, Mo. : London: Mosby
3. Fletcher, CDM. Bridge, JA. Hogendoorn, P., Mertens, F.WHO Classification of Tumours of Soft Tissue and Bone. Fourth Edition.2002
4. Ryan MI, Kevin BJ, Nathan L, Joseph AB.Intraosseous neurilemmoma involving the distal tibia and fibula: A case report.The Iowa Orthopaedic Journal.
5. K. Krishnan Unni Carrie Y. Inwards.Dahlin’s Bone Tumors, 6e.GENERAL ASPECTS AND DATA ON 10,165 CASES.
6. Chelsea P,Hamad G, Shweta B. Vikram Dogra.Schwannoma of the Tibial Nerve.Journal of Diagnostic Medical Sonography.2010
7. Manasa AM. Intraosseous Schwannoma of the Maxilla Mimicking a Periapical Lesion: A Diagnostic Challenge. Journal of Clinical and Diagnostic Research. 2015.
8. Kaihu Li et al.Giant intraosseous Schwannoma of the calcaneusInt J ClinExp Med 2016.
9. S.A. Lacerda et al.Intraosseous Schwannoma of Mandibular Symphysis: Case Report.Braz Dent J 2006.
10. Suzuki et al.Association between intraosseous schwannoma occurrence and the position of the intraosseous nutrient vessel: A case report.ONCOLOGY LETTERS.2016
(Abstract Full Text HTML) (Download PDF)
Like this:
Adamantinoma; An update
Vol 3 | Issue 2 | Sep-Dec 2017 | Page 16-19 | Ashish Gulia, Pankaj Kumar Panda.
Authors: Ashish Gulia [1], Pankaj Kumar Panda [1].
[1] Surgical Oncology (Orthopedic Oncology), 93, Ground Floor, Main Building, Bone & Soft tissue Services (Disease Management Group), Tata Memorial Hospital, Mumbai – 400012, India.
Address of Correspondence
Dr. Ashish Gulia,
Surgical Oncology (Orthopedic Oncology), 93, Ground Floor, Main Building, Bone & Soft tissue Services (Disease Management Group), Tata Memorial Hospital, Mumbai – 400012, India.
Email: aashishgulia@gmail.com
Abstract
Adamantinoma is a rare, malignant biphasic tumor with varied morphological patterns.Adamantinoma mostly occurs in the second to fifth decade and is slightly more common in men than women.The onset is insidious, and its course shows a slow, progressive character.Radiography is the initial and most reliable imaging modality for adamantinoma of bones because of the tumor’s classic location and appearance on a plain radiograph.Present management modalitieswhich includeen blocresection (mostly intercalary resection) with limb salvage and limb reconstruction. Chemotherapy and radiotherapy have no established role. Amputation does not improve survival but may be advisable in cases with local recurrence and in cases with few large, recurrent lesions where en bloc resection is not possible.
Keywords: Adamantinoma, malignant biphasic tumor, management.
References
1. Dahlin DC. Bone Tumors: General Aspects and Data on 6221 Cases. 3rded. Springfield, IL: Charles C Thomas; 1978. p. 296.
2. Kahn LB. Adamantinoma, osteofibrous dysplasia and differentiated adamantinoma. Skeletal Radiol 2003;32(5):245-258.
3. Fisher B. Primary adamantinoma of the tibia. Z Pathol 1913;12:422-441.
4. Van Rijn R, Bras J, Schaap G, van den Berg H, Maas M. Adamantinoma in childhood: Report of six cases and review of the literature. PediatrRadiol 2006;36(10):1068-1074.
5. Czerniak B, Rojas-Corona RR, Dorfman HD. Morphologic diversity of long bone adamantinoma. The concept of differentiated (regressing) adamantinoma and its relationship to osteofibrous dysplasia. Cancer 1989;64(11):2319-2334.
6. Mirra JM. Adamantinoma and fibrous dysplasia. InBone tumors 1sted. Mirra JM, editor. Philadelphia,PA: Lea &Febiger; 1989. p. 1203-1231.
7. Springfield DS, Rosenberg AE, Mankin HJ, Mindell ER. Relationship between osteofibrous dysplasia and adamantinoma. ClinOrthopRelat Res 1994;309:234-244.
8. Moon NF, Mori H. Adamantinoma of the appendicular skeleton-updated. ClinOrthopRelat Res 1986;204:215-237.
9. Lederer H, Sinclair AJ. Malignant synovioma simulating “adamantinoma of the tibia”. J PatholBacteriol 1954;67(1):163-168.
10. Van der Woude HJ, Hazelbag HM, Bloem JL, Taminiau AH, Hogendoorn PC. MRI of adamantinoma of long bones in correlation with histopathology. AJR Am J Roentgenol 2004;183(6):1737-1744.
11. Unni KK. Dahlin’s Bone Tumors: General Aspects and Data on 11,087 Cases. 5thed. Philadelphia, Pa: Lippincott-Raven; 1996. p. 333-342.
12. Hazelbag HM, Taminiau AHM, Fleuren GJ, Hogendoorn PC. Adamantinoma of the long bones. A clinicopathological study of thirty-two patients with emphasis on histologic subtype, precursor lesion, and biological behavior. J Bone Joint Surg Am 1994;76:1482-1499.
13. Weiss SW, Dorfman HD. Adamantinoma of long bone. An analysis of nine new cases with emphasis on metastasizing lesions and fibrous dysplasia-like changes. Hum Pathol 1977;8(2):141-153.
14. Bridge JA, Dembinski A, DeBoer J, Travis J, Neff JR. Clonal chromosomal abnormalities in osteofibrous dysplasia. Implications for histopathogenesis and its relationship with adamantinoma. Cancer 1994;73(6):1746-1752.
15. Ueda Y, Blasius S, Edel G, Wuisman P, Böcker W, Roessner A. Osteofibrous dysplasia of long bones-A reactive process to adamantinomatous tissue. J Cancer Res ClinOncol 1992;118(2):152-156.
16. Hazelbag HM, Fleuren GJ, vdBroek LJ, Taminiau AH, Hogendoorn PC. Adamantinoma of the long bones: Keratin subclass immunoreactivity pattern with reference to its histogenesis. Am J SurgPathol 1993;17(12):1225-1233.
17. Kanamori M, Antonescu CR, Scott M, Bridge RS Jr, Neff JR, Spanier SS, et al. Extra copies of chromosomes 7, 8, 12, 19, and 21 are recurrent in adamantinoma. J MolDiagn 2001;3(1):16-21.
18. Keeney GL, Unni KK, Beabout JW, Pritchard DJ. Adamantinoma of long bones. A clinicopathologic study of 85 cases. Cancer 1989;64(3):730-7.
19. Qureshi AA, Shott S, Mallin BA, Gitelis S. Current trends in the management of adamantinoma of long bones. An international study. J Bone Joint Surg Am 2000;82-A(8):1122-1131.
20. Bovée JV, van den Broek LJ, de Boer WI, Hogendoorn PC. Expression of growth factors and their receptors in adamantinoma of long bones and the implication for its histogenesis. J Pathol 1998;184(1):24-30.
(Abstract Full Text HTML) (Download PDF)
Like this:
Giant Cell Tumor Symposium Part 2
Vol 3 | Issue 2 | Sep-Dec 2017 | page:1 | Dr. Mandip Shah.
Author: Mandip Shah [1].
[1] Sparsh Orthopedic Oncology Clinic. Medicare Building 9th Floor, , B/H Town Hall, Ashram Road, 380006 – Ahmedabad., India.
Address of Correspondence
Dr. Mandip Shah
Sparsh Orthopedic Oncology Clinic. Medicare Building 9th Floor, , B/H Town Hall, Ashram Road, 380006 – Ahmedabad., India
Email: mandipshah@gmail.com
Giant Cell Tumor Symposium Part 2
We are back with the second part of the Giant Cell Tumor Symposium for Journal of Bone and Soft Tissue Tumors.
Two very important aspects are covered in this part. First is the histopathological concepts regarding GCT. There is lot of new knowledge that is available in recent years and that has significantly impacted the diagnosis, management and prognosis of GCT. Histopathological assessment play a major role in terms of determining the behaviour of GCT. Current understanding of molecular pathogenesis of GCTB particularly RANK on osteoclast-like GCs and RANKL on stromal cells and development of newer agents such as denosumab and INF-α has tremendously impacted management of patients with GCTB. This aspect is elaborated in the first article. The second article builds on these concepts and describes how this is used for adjuvent therapy for GCTB. Authors of both the authors have taken tremendous effort to make both these articles good and current. Also these two now conclude the GCT Symposium and cover all aspect of GCTB
Please write to us regarding your suggestions and opinions
Regards
Dr. Mandip Shah
(Abstract Full Text HTML) (Download PDF)
Like this:
Histopathology of Giant-cell Tumor of Bone – Current Concept
Vol 3 | Issue 2 | Sep-Dec 2017 | Page 2-5| Sanjeev Shah.
Authors: Sanjeev Shah [1].
[1] Department of Pathology, Unipath Laboratory Specialty Ltd, Beside JMC House, Ahmedabad, Gujarat, India.
Address of Correspondence
Dr. Sanjeev Shah,
102, First floor, Sanoma Plaza, Opp. Parimal Garden, Beside JMC House, Ellisbridge, Ahmedabad – 380006, Gujarat, India.
E-mail: dcp72002@yahoo.com
Abstract
GCTB is a primary osteolytic bone tumor which can recurrence, undergo metastasis, and malignant transformation. Current understanding of molecular pathogenesis of GCTB particularly RANK on osteoclast-like GCs and RANKL on stromal cells and development of newer agents such as denosumab and INF-α has tremendously impacted management of patients with GCTB.
Keywords: Giant-cell tumor of bone histopathology, current concept.
References
1. Turcotte RE. Giant cell tumor of bone. OrthopClin North Am 2006;37:35-51.
2. Georgi PG, Svetoslav S, Iva ND, Boycho L. Giant cell tumor of bone: Current review of morphological, clinical, radiological, and therapeutic characteristics. J Clin Exp Investig 2014;5:475-85.
3. Nielsen GP, Andrew ER, Vikram D, Francis JH, Susan VK, Daniel IR. Diagnostic Pathology Bone: Amirsys; 2013. p. 371-95.
4. Fletcher CD, Bridge JA, Hogendoorn P, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: France IARC Press; 2013. p. 321-4.
5. Dominkus M, Ruggieri P, Bertoni F, Briccoli A, Picci P, Rocca M, et al. Histologically verified lung metastases in benign giant cell tumours–14 cases from a single institution. Int Orthop 2006;30:499-504.
6. Kay RM, Eckardt JJ, Seeger LL, Mirra JM, Hak DJ. Pulmonary metastasis of benign giant cell tumor of bone. Six histologically confirmed cases, including one of spontaneous regression. Clin Orthop Relat Res 1994;302:219-30.
7. Gamberi G, Benassi MS, Böhling T, Ragazzini P, Molendini L, Sollazzo MR, et al. Prognostic relevance of C-myc gene expression in giant-cell tumor of bone. J Orthop Res 1998;16:1-7.
8. Schoedel KE, Greco MA, Stetler-Stevenson WG, Ohori NP, Goswami S, Present D, et al. Expression of metalloproteinases and tissue inhibitors of metalloproteinases in giant cell tumor of bone: An immunohistochemical study with clinical correlation. Hum Pathol 1996;27:1144-8.
9. Hoch B, Inwards C, Sundaram M, Rosenberg AE. Multicentric giant cell tumor of bone. Clinicopathologic analysis of thirty cases. J Bone Joint Surg Am 2006;88:1998-2008.
10. Dhillon MS, Prasad P. Multicentric giant cell tumour of bone. ActaOrthopBelg 2007;73:289-99.
11. Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer 2003;97:2520-9.
12. Nascimento AG, Huvos AG, Marcove RC. Primary malignant giant cell tumor of bone: A study of eight cases and review of the literature. Cancer 1979;44:1393-402.
13. Anract P, De Pinieux G, Cottias P, Pouillart P, Forest M, Tomeno B, et al. Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: A review of 29 cases. Int Orthop 1998;22:19-26.
14. Dickson BC, Li SQ, Wunder JS, Ferguson PC, Eslami B, Werier JA, et al. Giant cell tumor of bone express p63. Mod Pathol 2008;21:369-75.
15. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 2013;45:1479-82.
16. Akpalo H, Lange C, Zustin J. Discovered on gastrointestinal stromal tumour 1 (DOG1): A useful immunohistochemical marker for diagnosing chondroblastoma. Histopathology 2012;60:1099-106.
17. Cleven AG, Briaire-de Bruijn I, Szuhai K, Bovee JV. DOG1 expression in giant-cell-containing bone tumours. Histopathology 2016;68:938-45.
18. Althof PA, Ohmori K, Zhou M, Bailey JM, Bridge RS, Nelson M, et al. Cytogenetic and molecular cytogenetic findings in 43 aneurysmal bone cysts: Aberrations of 17p mapped to 17p13.2 by fluorescence in situhybridization. Mod Pathol 2004;17:518-25.
19. Oliveira AM, Perez-Atayde AR, Dal Cin P, Gebhardt MC, Chen CJ, Neff JR, et al. Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. Oncogene 2005;24:3419-26.
20. Kim Y, Nizami S, Goto H, Lee FY. Modern interpretation of giant cell tumor of bone: Predominantly osteoclastogenic stromal tumor. Clin Orthop Surg 2012;4:107-16.
21. López-Pousa A, Martín Broto J, Garrido T, Vázquez J. Giant cell tumour of bone: New treatments in development. Clin Transl Oncol 2015;17:419-30.
22. Xu SF, Adams B, Yu XC, Xu M. Denosumab and giant cell tumour of bone-a review and future management considerations. Curr Oncol 2013;20:e442-7.
23. Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012;18:4415-24.
24. Heymann D. Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences. J Bone Oncol 2012;1:2-11.
25. Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X, et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J ClinPathol 2002;117:210-6.
(Abstract Full Text HTML) (Download PDF)
Like this: